Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy
NCT06433050
Recruiting
The goal of this clinical trial is to learn if sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, works to treat symptomatic, nonobstructive hypertrophic cardiomyopathy (noHCM) in adult patients. It will also learn about the safety of sotagliflozin in this patient population. The main questions it aims to answer are: 1. Will sotagliflozin be well tolerated in patients with nonobstructive HCM? 2. Will sotaglifozin improve exercise capacity, diastolic dysfunction and/or physical functioning in pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Hypertrophic Cardiomyopathy Without Obstruction
Register for Updates
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
NCT05249101
Recruiting
This study is a Phase 1b/2, dose-escalation, randomized, multicenter study to assess the efficacy, safety, tolerability, and PK of ivaltinostat in combination with capecitabine and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropyrimidine-based chemotherapy (e.g., FOLFIRINOX). In Phase 1b, 3 dose levels of ivaltinostat will be studied in combination with a fixed dose of capecitabine to determine the RP2D of i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: Penn State Hershey Cancer Institute, Hershey, Pennsylvania
Conditions: Metastatic Pancreatic Adenocarcinoma
Register for Updates
Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease
NCT05138848
Recruiting
Dementia caused by Alzheimer's disease affects approximately 5.6 million adults over age 65, with costs expected to rise from $307 billion to $1.5 trillion over the next 30 years. Behavioral interventions have shown promise for mitigating neurodegeneration and cognitive impairments. Sleep is a modifiable health behavior that is critical for cognition and deteriorates with advancing age and Alzheimer's disease. Thus, it is a priority to examine whether improving sleep modifies Alzheimer's disease... Read More
Gender:
ALL
Ages:
Between 65 years and 85 years
Trial Updated:
01/15/2025
Locations: UPMC Western Psychiatric Hospital, Pittsburgh, Pennsylvania
Conditions: Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Sleep, Cognitive Change, Amyloid
Register for Updates
Verapamil for Neuroprotection in Stroke
NCT03347786
Recruiting
The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/15/2025
Locations: St Mary Medical Center, Langhorne, Pennsylvania
Conditions: Ischemic Stroke
Register for Updates
The Lily Device Trial
NCT06786078
Recruiting
The goal of this clinical trial is to test if the Lily Device works to reduce chemotherapy induced hair loss in patients. It will also learn about the safety of the Lily Device. The main questions it aims to answer is: * Do patient preserve their hair using the Lily Device after 4 cycles of chemotherapy, when hair preservation is a Grade ≤1 graded by an independent healthcare professional on the Common Terminology Criteria for Adverse Events (CTCAE)? * What is the subject incidence of Grade 1 o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Guthrie Sayer Medical Centre, Sayre, Pennsylvania
Conditions: Chemotherapy Induced Alopecia
Register for Updates
Testing Interventions for Mobility Through Exercise (TIME)
NCT05725564
Recruiting
In this project, the team plans to test the impact of FAST, its brief home-based strength training program which includes performance goal setting, to a program for home (BAND TOGETHER) that is similar to one offered by Silver Sneakers, available online to millions of older adults, and includes strength, balance, and aerobic exercises. The team hypothesizes that the brief program (FAST) will improve leg function better than the standard program (BAND TOGETHER), by encouraging older adults to be... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
01/14/2025
Locations: Penn State College of Medicine, Hershey, Pennsylvania
Conditions: Walking, Difficulty, Mobility Limitation
Register for Updates
Evaluating Treatment of ADHD in Children with Down Syndrome
NCT04219280
Recruiting
Children with Down syndrome (DS) have a 3-5 time greater prevalence of Attention Deficit Hyperactivity Disorder (ADHD) than typically developing (TD) children. Despite this higher risk of ADHD, rates of stimulant medication treatment are disproportionately low in children with DS+ADHD, even though stimulants are the most efficacious ADHD treatment and are recommended by consensus guidelines for use in children with intellectual disability and ADHD. The investigators propose the first randomized... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
01/14/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Down Syndrome, ADHD
Register for Updates
Concussion Treatment in Older Adults
NCT05849064
Recruiting
The purpose of this study is to conduct the first randomized control trial for targeted treatments for concussion in adults 50 years or older. Participants will be enrolled at their first concussion clinical visit (V1) and their second study visit will occur after (up to 7 days) or concurrently with the participant's second concussion clinical visit, typically (but not limited to) between 21-31 days from V1.
Gender:
ALL
Ages:
Between 50 years and 99 years
Trial Updated:
01/13/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Concussion, Mild
Register for Updates
A Comparison of Two Brief Suicide Prevention Interventions Tailored for Youth on the Autism Spectrum
NCT05398250
Recruiting
Rates of suicide have increased significantly over the past two decades, particularly among youth. Compared to the general population, autistic people are significantly more likely to think about suicide, attempt suicide, and die by suicide. Autistic individuals have identified suicide prevention as a top research priority; however, little is known about how to best help autistic youth at risk for suicide. The purpose of this study is to compare the effectiveness, feasibility, and acceptability... Read More
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
01/13/2025
Locations: Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Suicidal Ideation, Suicidal and Self-injurious Behavior, Suicide, Autism Spectrum Disorder
Register for Updates
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
NCT03589339
Recruiting
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2025
Locations: St Luke's University Health Network, Bethlehem, Pennsylvania
Conditions: Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastasis From Malignant Melanoma of Skin (Disorder), Metastasis From Malignant Tumor of Bladder (Disorder), Metastasis From Malignant Tumor of Liver, Metastatic Renal Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC
Register for Updates
Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset
NCT05685745
Recruiting
The goal of the Tiny Baby Collaborative Multicenter Inventory of Neonatal-Perinatal Interventions (MINI) minimum dataset is to serve as a registry detailing the outcomes and practices for all deliveries and infants admitted to intensive care at 22-23 weeks' gestation at participating hospitals.
Gender:
ALL
Ages:
Between 0 years and 1 year
Trial Updated:
01/10/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Infant, Extremely Premature, Obstetric Labor, Premature, Premature Birth, Intensive Care, Neonatal, Intensive Care Units, Neonatal
Register for Updates
Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)
NCT05579327
Recruiting
This is a double-blind, randomized phase 3 multicenter placebo-controlled study in at least 16 evaluable male participants diagnosed with MCT8 deficiency. Male participants, from 4 years of age (at randomization) and having demonstrated stable maintenance treatment with tiratricol, will be randomized to receive placebo or tiratricol for 30 days or until reaching rescue criterion (serum total triiodothyronine \[T3\] \> upper limit of normal \[ULN\] of the participant's normal range, for a sample... Read More
Gender:
MALE
Ages:
4 years and above
Trial Updated:
01/10/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome
Register for Updates